Bleomycin (BLM), which produces little hematologic toxicity, and methotrexate (MTX) have reported response rates of 13% and 25% respectively in epidermoid lung cancer. Given together, they induced regressions in 53% of evaluable patients with epidermoid carcinomas. The nitrosoureas CCNU and methyl-CCNU also possess similar single-agent activity in this histologic type of lung tumor. At least a single objective response of non-small cell pulmonary carcinoma to the nonmyelosuppressive nitrosourea streptozotocin (STZ) has been observed. The authors therefore studied the effects of combined therapy with BLM, MTX, and STZ in patients with epidermoid carcinoma of the lung.
|Original language||English (US)|
|Number of pages||3|
|Journal||Cancer Treatment Reports|
|State||Published - Sep 15 1978|
ASJC Scopus subject areas
- Cancer Research